2021 Year in Review - Triple-Negative Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer | December 14, 2021
Sacituzumab govitecan-hziy, for the second-line treatment of patients with metastatic triple-negative breast cancer, is a cytotoxic drug that has specific storage, reconstitution, and administration instructions for adherence.
2021 Year in Review - Triple-Negative Breast Cancer | December 14, 2021
The optimal risk-to-benefit dosage of sacituzumab govitecan-hziy is 10 mg/kg, calculated from dose-escalation and dose-expansion studies.
2021 Year in Review - Triple-Negative Breast Cancer | December 14, 2021
Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes.
- 1
- 2
Page 2 of 2
Results 11 - 13 of 13
Results 11 - 13 of 13